MTD
Mettler-Toledo International Inc.
MTD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MTD overall, supported by stronger fundamentals and stronger modeled upside.
MTD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
MTD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MTD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 31x | $1,406 | -19% |
| Forward | 34x | $1,731 | — |
| Fair | 36x | $1,655 | -4.4% |
| Current | 38x | $1,731 | — |
| Expensive | 46x | $2,122 | +23% |
Historical ranges are pointers, not guarantees.
MTD's PE is in its fair range at 38x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MTD in the historical PE scenario, which offers more potential upside but is not a forecast.
MTD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MTD, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MTD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $51.52 | +12% |
| Q3 2026 | $46.08 | +15% |
| Q2 2026 | $44.36 | +12% |
| Q1 2026 | $42.57 | +6.3% |
| Q4 2025 | $42.05 | +3.9% |
| Q3 2025 | $40.05 | +8% |
| Q2 2025 | $39.44 | +8.5% |
| Q1 2025 | $40.05 | +12% |
| Q4 2024 | $40.48 | +13% |
MTD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MTD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +6.3% |
| Q2 2026 | $1B | +4.5% |
| Q1 2026 | $947.1M | +7.2% |
| Q4 2025 | $1.1B | +8.1% |
| Q3 2025 | $1B | +7.9% |
| Q2 2025 | $983.2M | +3.9% |
| Q1 2025 | $883.7M | -4.6% |
| Q4 2024 | $1B | +12% |
MTD's revenue has grown year over year for six quarters in a row: $1.1B last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +1.3 points |
| Q2 2026 | 28% | +2.9 points |
| Q1 2026 | 22% | -0.7 points |
| Q4 2025 | 29% | -1 points |
| Q3 2025 | 26% | -1 points |
| Q2 2025 | 25% | -0.4 points |
| Q1 2025 | 23% | -1 points |
| Q4 2024 | 30% | +5.2 points |
MTD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MTD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MTD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $281.5M | +2.4% |
| Q2 2026 | $282.6M | +33% |
| Q1 2026 | $122.4M | -31% |
| Q4 2025 | $184.1M | -18% |
| Q3 2025 | $274.9M | +18% |
| Q2 2025 | $212.5M | -9.1% |
| Q1 2025 | $177.2M | +2.7% |
| Q4 2024 | $224.9M | -9.7% |
MTD's free cash flow has been positive every quarter for six years: $871M over the past year, down 2.1% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MTD on cash flow, with more consistent year-over-year improvement.
MTD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -148K shares |
| 1 year | -2.7% | -552K shares |
| 3 years | -8.5% | -1.9M shares |
| 5 years | -14% | -3.4M shares |
| Available history | -19% | -4.6M shares |
MTD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $226.2M |
| Q2 2026 | $206.3M |
| Q1 2026 | $206.3M |
| Q4 2025 | $143.7M |
| Q3 2025 | $218.7M |
| Q2 2025 | $218.7M |
| Q1 2025 | $218.7M |
| Q4 2024 | $212.5M |
MTD spent $782M buying back its own shares over the past year, down 9.9% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MTD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 1.8x | Healthy |
MTD's net debt is about 1.6 years of its operating earnings (EBITDA), down from 1.9 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MTD on leverage, with a lower net debt burden relative to earnings.
MTD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 86.2 | Overbought |
MTD's weekly RSI is 74 (overbought) and its Stochastic is 86 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MTD PE vs Healthcare Sector
| Metric | MTD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 26x | 45% above |
| PE % | 58 | 29 | 29 pts above |
MTD is trading at 38x earnings, a 45% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MTD on valuation relative to its sector.
MTD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,621.0 | 6.8% above |
| 20 week MA | $1,465.0 | 18% above |
| 50 week MA | $1,359.5 | 27% above |
| 100 week MA | $1,302.9 | 33% above |
| 200 week MA | $1,308.6 | 32% above |
MTD has climbed back above all five of its weekly moving averages, and it's now 32% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MTD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $792.8 | $1,140.2 | +44% |
| 2021 | $1,140.2 | $1,626.2 | +43% |
| 2022 | $1,626.2 | $1,439.1 | -12% |
| 2023 | $1,439.1 | $1,213.0 | -16% |
| 2024 | $1,213.0 | $1,234.2 | +1.8% |
| 2025 | $1,234.2 | $1,420.1 | +15% |
| 2026 YTD | $1,420.1 | $1,730.9 | +22% |
MTD has finished higher in four of the last six years. It's up 22% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MTD on returns for 2026, with the stronger performance.